OPGN - OpGen, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9800
+0.0100 (+0.51%)
At close: 4:00PM EDT

1.9900 +0.01 (0.51%)
After hours: 7:20PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.9700
Open2.0700
Bid1.9700 x 1800
Ask1.9800 x 1100
Day's Range1.9501 - 2.0700
52 Week Range0.9200 - 15.2000
Volume1,033,409
Avg. Volume2,153,426
Market Cap29.839M
Beta (5Y Monthly)-1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Thomson Reuters StreetEvents

    Edited Transcript of OPGN earnings conference call or presentation 7-May-20 8:30pm GMT

    Q1 2020 OpGen Inc Earnings Call

  • Thomson Reuters StreetEvents

    Edited Transcript of OPGN earnings conference call or presentation 24-Mar-20 8:30pm GMT

    Q4 2019 OpGen Inc Earnings Call

  • The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours.On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's impact, none of the Nasdaq- or NYSE-listed biotech stocks hit 52-week highs or lows.Stocks In Focus InVitae Withdraws FY20 Guidance Due To Pandemic, Plans Offering InVitae Corp (NYSE: NVTA), a medical genetics company, pre-announced first-quarter results and said it expects revenue of more than $63 million, up 55% year-over-year, billable tests of 147,000, up 65%, and non-GAAP cash burn of less than $100 million. Analysts expect revenue of $60.3 million.Citing the unknown duration and extent of COVID-19's impact on its business and the health care system in general, the company said it is withdrawing its guidance for 2020.Separately, the company announced an underwritten public offering of 17.78 million shares priced at $9 per share. All the shares are being sold by the company. The company expects the offering to close April 6 and to raise gross proceeds of about $16 million.The stock was down 11.96% at $10.31 in Thursday's premarket session. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Novartis Terminates Agreement To Sell Sandoz US Assets To Aurobindo Novartis AG (NYSE: NVS) said it has mutually agreed with Aurobindo Pharma to terminate a previously announced deal to sell the Sandoz U.S. generic oral solids and dermatology businesses to Aurobindo. The decision follows a lack of FTC approval for the transaction within anticipated timelines.Novartis shares were adding 1.57% to $82.20 in premarket trading Thursday.Nevro Forecasts Q1 Revenue Shortfall, Withdraws 2020 Guidance Nevro Corp (NYSE: NVRO) announced preliminary unaudited worldwide revenue for the first quarter of $86.4 million to $86.9 million, up from $82.1 million a year ago. This compares to the $94.96-million consensus estimate. The company attributed the potential shortfall to a rapid deceleration in March due to COVID-19 shelter-in-place policies and restrictions on elective surgical procedures.The company also withdrew its 2020 guidance issued in late February due to the rapidly evolving environment and continued uncertainties related to COVID-19.Separately, the company announced a public offering of 1.625 million shares of common stock and $165 million in aggregate principal amount of convertible senior notes due 2025.The stock fell 3.86% to $86 in after-hours trading.OpGen Closes On Curetis Purchase OpGen Inc (NASDAQ: OPGN) announced the consummation of its proposed acquisition of Dutch molecular diagnostics company Curetis N.V. OpGen shares paid as consideration for the sale will be distributed to Curetis, which will be dissolved and delisted from the Euronext exchange.OpGen shares were trading 5.44% higher at $2.52 in Thursday's premarket session. See also: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty Eiger's HDV Study To Be Delayed, Company To Support Studies Of Peginterferon Lambda In COVID-19 Issuing an update on clinical development activity and business operations, Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) said it has taken appropriate steps to ensure the safety of patients and integrity of the HDV Phase 3 D-LIVR trial. The trial is evaluating lonafarnib and ritonavir with or without PEGylated interferon-alfa-2a in patients with chronic hepatitis D virus infection.It now expects the COVID-19 pandemic to lead to the shifting of the completion of enrollment in the study to 2021.The company also said it has begun supporting multiple investigator-sponsored studies of peginterferon lambda in COVID-19."These studies will assess a 180 mcg, once-weekly, subcutaneous dose of Lambda, and will enroll at academic centers across the U.S., as well as international sites," the company said.The shares advanced 6.27% to $6.27 in after-hours trading.Affimed's Lead Drug Gets Orphan Drug Designation In T-Cell Lymphoma Affimed NV (NASDAQ: AFMD) said the FDA has granted orphan drug designation to AFM13, its lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.Affimed shares were up 6.92% to $1.70 in the premarket session. BioCryst Names Anthony Doyle As CFO BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the appointment of Anthony Doyle as CFO. Doyle previously served as a global contract research organization's CFO.In premarket trading Thursday, BioCryst shares were adding 0.26% to $1.90.Boston Scientific Lowers Q1 Revenue Guidance Due To COVID-19 Impact Boston Scientific Corporation (NYSE: BSX) lowered its first-quarter revenue growth guidance to flat to slightly up from its previous estimate for 10-12% growth. The company attributed the predicament to a significant decline in procedural volumes in March due to COVID-19 impact.Humanigen's Lenzilumab Gets FDA Nod For Compassionate Use In COVID-19 Patients Humanigen Inc (OTC: HGEN) said the FDA approved the administration of its lenzilumab for COVID-19 patients under individual patient emergency IND applications to patients under its compassionate use program.The company said it is advancing plans to conduct a multi-center, Phase 3 study of lenzilumab for the prevention of acute respiratory distress syndrome, ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 infection.Applied Therapeutics Opens IND With FDA For AT-001 To Treat COVID-19-Related Lung Inflammation, Cardiomyopathy Applied Therapeutics Inc (NASDAQ: APLT) said it has opened an INDA with the FDA for AT-001 to treat acute lung inflammation and cardiomyopathy in critical COVID-19 patients. The company noted that multiple AT-001 investigator-initiated trials are now underway to address these two issues.Vir, Alnylam Expand Existing Collaboration To Include Additional Targets In COVID-19 Treatment Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion of their existing collaboration for RNAi therapeutics for infectious diseases. The expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry.Vir shares were gaining 2.45% to $30.50 in premarket trading Thursday.Related Link: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates See more from Benzinga * 10 Biotech Winners And Losers In Q1 * The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Nano-Cap OpGen Skyrockets On COVID-19 Connection
    Benzinga

    Nano-Cap OpGen Skyrockets On COVID-19 Connection

    OpGen Inc (NASDAQ: OPGN) shares were ripping higher Monday in reaction to an announcement regarding a COVID-19 test kit from German molecular diagnostics company Curetis, which OpGen has agreed to merge with.Curetis said it has begun offering a CE-IVD-certified real-time PCR test kit for SARS-CoV-2, the virus causing COVID-19, OpGen said.The test kit, developed and manufactured by Curetis' Chinese strategic partner BGI, was cleared by the Chinese authorities in January. It was CE-IVD certified on Feb. 28. CE certification indicates the product is in conformity with health, safety and environmental protection standards for products sold in the European Economic Area.The BGI COVID-19 test kit allows labs to perform testing of nasopharyngeal swabs and bronchoalveolar lavage fluid. It has all necessary reagents and controls to test up to 48 patients in just a few hours, according to OpGen. The test is to be made available to labs in Europe through Curetis' network of distribution partners as well as directly by Curetis in countries where its distribution partners are not equipped to supply the test at short notices."We commend both Curetis and BGI Group for swiftly bringing this important product to market in a time of greatest need. As Covid-19 spreads across the globe, rapid testing technologies will be critical to the containment and ultimate treatment of the outbreak in Europe and beyond," OpGen CEO Evan Jones said in a statement. The stock was rallying 105.96% higher to $4.14 at the time of publication Monday. Related Links:The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review 8 Biotechs With Coronavirus Vaccines In Development See more from Benzinga * 5 Reasons Why Amazon Is Morgan Stanley's Top Pick * 8 Biotechs With Coronavirus Vaccines In Development * BioNTech Says Coronavirus Vaccine Testing Begins Next Month In 'Project Lightspeed'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Teladoc to Buy InTouch Health, Expand Reach in Virtual Care
    Zacks

    Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

    Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.

  • Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
    Zacks

    Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

    Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

  • Adopt Rising P/E Technique With These 5 Top-Ranked Stocks
    Zacks

    Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

    What bargain hunting? Stocks with a rising P/E can also be worth buying too.

  • Thomson Reuters StreetEvents

    Edited Transcript of OPGN earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 OpGen Inc Earnings Call

  • OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates

    OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -28.46% and -28.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know

    OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...

  • Benzinga

    The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...

  • Thomson Reuters StreetEvents

    Edited Transcript of OPGN earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 OpGen Inc Earnings Call

  • Benzinga

    New Month, New Market: Resetting For September

    Even though it’s a shortened trading week in the States thanks to the Labor Day holiday, the first days of September have felt like a fresh start. That might be a good or bad thing depending on how you ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Slack Technologies (NYSE: WORK ) shares were ...

  • Benzinga

    OpGen To Merge With German Molecular Diagnostics Company Curetis In $24M Deal

    OpGen, a precision medicine company that uses molecular diagnostics and informatics to help combat infectious disease, announced a definitive agreement to acquire Curetis GmbHm — a wholly owned subsidiary of Curetis, which owns the Curetis Group business. The deal provides for Curetis receiving 2.66 million new shares of OpGen, representing about 72.5% of outstanding shares, valuing the combined business at about $24 million.

  • OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For June 14

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ArQule, Inc. (NASDAQ: ARQL ) shares were up ...